Albuquerque, NM, United States of America

Wei Xiong

This inventor holds 17 USPTO granted patents and 1 published patent application, plus 4 CIPO patents and 4 EPO patents, primarily in Optical Imaging. Top assignees: Amo Wavefront Sciences, LLC, The University of Texas System, Amo Development, LLC. Active years: 2011-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wei Xiong. Retrieved from https://idiyas.com/inventor/wei-xiong-uvclxioy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 1)

% Patents Active = 94.1

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 6.2

ph-index = 5

Forward Citations = 102(Granted Patents)

Location History:

Pearland, TX (US) (2019 - 2022)
Albuquerque, NM (US) (2011 - 2023)
Houston, TX (US) (2021 - 2024)

Company Filing History:

10 out of 59

Amo Wavefront Sciences, LLC

patents

5 out of 5,640

The University of Texas System

Years Active: 2011-2025

Loading Chart...

Areas of Expertise:

Connexin 43

Cataract Surgery

Optical Measurement

Antibody Treatment

Cancer Detection

Tear Film Breakup

Spinal Cord Injury

Surface Shape Measurement

Intraocular Lens

Osteolytic Tumor

Corneal Topography

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12503500 - CONNEXIN 43 (Cx43) HEMICHANNEL-BINDING ANTIBODIES (2025-12-23),

2. 11912758 - Methods of treating metastasis, including inhibiting bone cancer metastasis, by administering an antibody which binds connexin 43 (Cx43) hemichannel (2024-02-27),

3. 11730359 - Optical imaging and measurement systems and methods for cataract surgery and treatment planning (2023-08-22),

4. 11498963 - Anti-LILRB antibodies and their use in detecting and treating cancer (2022-11-15),

5. 10889637 - Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies (2021-01-12),

6. 10631724 - Method and system for dynamically measuring tear film breakup and irregularity using corneal topography and wavefront aberrometry (2020-04-28),

7. 10583039 - Method and system for eye measurements and cataract surgery planning using vector function derived from prior surgeries (2020-03-10),

8. 10582847 - Method and system for eye measurements and cataract surgery planning using vector function derived from prior surgeries (2020-03-10),

9. 10582846 - Method and system for eye measurements and cataract surgery planning using vector function derived from prior surgeries (2020-03-10),

10. 10506923 - Optical imaging and measurement systems and methods for cataract surgery and treatment planning (2019-12-17),

11. 10501538 - Anti-LILRB antibodies and their use in detecting and treating cancer (2019-12-10),

12. 10456026 - Apparatus, system, and method for intraocular lens power calculation using a regression formula incorporating corneal spherical aberration (2019-10-29),

13. 9468369 - Model eye producing a speckle pattern having a reduced bright-to-dark ratio for use with optical measurement system for cataract diagnostics (2016-10-18),

14. 8622546 - Method of locating valid light spots for optical measurement and optical measurement instrument employing method of locating valid light spots (2014-01-07),

15. 8260024 - Systems and methods for measuring surface shape (2012-09-04),

Title: Innovations and Contributions of Inventor Wei Xiong

Introduction

Wei Xiong is a prominent inventor based in Albuquerque, NM, with a remarkable portfolio of 16 patents. His work primarily focuses on advancements in medical treatments and optical imaging technologies. Xiong's innovative contributions have the potential to significantly impact cancer treatment and cataract surgery.

Latest Patents

Among his latest patents, Wei Xiong has developed methods for treating metastasis, particularly in inhibiting bone cancer metastasis. This involves administering an antibody that binds to connexin 43 (Cx43) hemichannels. His patents also include antibodies that can either inhibit or activate Cx43 channel opening, providing methods for detecting or treating cancers. Additionally, he has created optical imaging and measurement systems for cataract surgery, which include a corneal topography subsystem and a wavefront aberrometer subsystem, all designed to enhance diagnostic capabilities.

Career Highlights

Wei Xiong has worked with notable organizations such as Amo Wavefront Sciences, LLC and the University of Texas System. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Thomas Daniel Raymond and Stephen W. Farrer. Their collaborative efforts have further advanced the research and development of innovative medical technologies.

Conclusion

Wei Xiong's contributions to the fields of cancer treatment and optical imaging exemplify the impact of innovation in medicine. His patents and collaborations highlight the importance of research in improving healthcare outcomes.

Profile summary based on public USPTO records.